Abstract
Background and Purpose
Cangrelor is a P2Y12 inhibitor that presents the advantage of having a short half-life. Its use may be helpful in the management of antiplatelet therapy for patients with intracranial aneurysms treated by stent-assisted coiling or flow-diverter stents. The purpose of this study was to report early experiences in using cangrelor for such indications.
Material and Methods
From October 2017 to November 2018, 7 consecutive patients (5 females, 2 males, mean age = 56 years) were managed with cangrelor as antiplatelet therapy, combined with aspirin, for stent-assisted coiling embolization and flow-diverter embolization of challenging intracranial aneurysms. Anti-aggregation protocols, including cangrelor, were systematically recorded. Treatment-related complications (minor/major hemorrhagic complications, ischemic complications) as well as clinical and angiographic outcomes (evaluated at 8.7 ± 4.2 and 8.75 ± 10 months, respectively) were retrospectively analyzed.
Results
Of the aneurysms 71.4% (5 out of 7) were ruptured and treated in the acute phase. In one case cangrelor was used as an alternative to clopidogrel in an asymptomatic hemorrhagic complication after stent-assisted coiling for better control of a possible worsening of the intracranial bleeding. Of the patients, 1 (14%) with a complex ruptured MCA aneurysm treated with a flow-diverter stent experienced a severe intracranial hemorrhage, which occurred after switching the cangrelor to ticagrelor and eventually led to death. No hemorrhagic complications under cangrelor were recorded for the six remaining patients. No mRS worsening was observed at discharge, except for the patient who died and six out of the seven patients had a mRS ≤2 at follow-up.
Conclusion
Cangrelor is a new antiplatelet therapy with a P2Y12 inhibiting effect, with a rapid onset and offset of action, owing to its short half-life. This cases series presents a pilot experience with promising results in terms of antiplatelet management for challenging intracranial aneurysms treated by stent assisted coiling or flow-diverter stents.
Similar content being viewed by others
Abbreviations
- ACA:
-
Anterior cerebral artery
- DSA:
-
Digital subtraction angiography
- FDS:
-
Flow diverter stent
- ICA:
-
Internal carotid artery
- MCA:
-
Middle cerebral artery
- mRS:
-
Modified Rankin Scale
- PCI:
-
Percutaneous coronary intervention
References
Fiorella D, Thiabolt L, Albuquerque FC, Deshmukh VR, McDougall CG, Rasmussen PA. Antiplatelet therapy in neuroendovascular therapeutics. Neurosurg Clin N Am. 2005;16:517–40.
Narata AP, Amelot A, Bibi R, Herbreteau D, Angoulvant D, Gruel Y, Janot K. Dual antiplatelet therapy combining aspirin and ticagrelor for intracranial stenting procedures: A retrospective single center study of 154 consecutive patients with unruptured aneurysms. Neurosurgery. 2019;84:77-83.
Webster TD, Vaishnava P, Eagle KA. Perioperative management of dual anti-platelet therapy. Hosp Pract. 2016;44:237–41.
Song JW, Soh S, Shim JK. Dual antiplatelet therapy and non-cardiac surgery: Evolving issues and anesthetic implications. Korean J Anesthesiol. 2017;70:13–21.
Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med. 2015;372:196–7.
Norgard NB. Cangrelor: A novel P2Y12 receptor antagonist. Expert Opin Investig Drugs. 2009;18:1219–30.
Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50:27–35.
Roy D, Milot G, Raymond J. Endovascular treatment of unruptured aneurysms. Stroke. 2001;32:1998–2004.
O’kelly CJ, Krings T, Fiorella D, Marotta TR. A novel grading scale for the angiographic assessment of intracranial aneurysms treated using flow diverting stents. Interv Neuroradiol. 2010;16:133–7.
Cekirge HS, Saatci I. A new aneurysm occlusion classification after the impact of flow modification. AJNR Am J Neuroradiol. 2016;37:19–24.
Iosif C, Mounayer C, Yavuz K, Saleme S, Geyik S, Cekirge HS, Saatci I. Middle cerebral artery bifurcation aneurysms treated by extrasaccular flow diverters: Midterm angiographic evolution and clinical outcome. AJNR Am J Neuroradiol. 2017;38:310–6.
Michelozzi C, Darcourt J, Guenego A, Januel AC, Tall P, Gawlitza M, Bonneville F, Cognard C. Flow diversion treatment of complex bifurcation aneurysms beyond the circle of Willis: Complications, aneurysm sac occlusion, reabsorption, recurrence, and jailed branch modification at follow-up. J Neurosurg. 2018 Dec 21:1-12. doi: 10.3171/2018.
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA; CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data. Lancet. 2013;382:1981–92.
Alexopoulos D, Pappas C, Sfantou D, Lekakis J. Cangrelor in percutaneous coronary intervention: Current status and perspectives. J Cardiovasc Pharmacol Ther. 2018;23:13–22.
Keating GM. Cangrelor: A review in percutaneous coronary intervention. Drugs. 2015;75:1425–34.
Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Abnousi F, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL; CHAMPION PHOENIX Investigators. Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention: The CHAMPION PHOENIX trial. JACC Cardiovasc Interv. 2016;9:1905–13.
Aguilar-Salinas P, Agnoletto GJ, Brasiliense LBC, Santos R, Granja MF, Gonsales D, Aghaebrahim A, Sauvageau E, Hanel RA. Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: Preliminary experience in a single-center pilot study. J Neurointerv Surg. 2019;11:347-51.
Marosfoi M, Clarencon F, Langan ET, King RM, Brooks OW, Tamura T, Wainwright JM, Gounis MJ, Vedantham S, Puri AS. Acute thrombus formation on phosphorilcholine surface modified flow diverters. J Neurointerv Surg. 2018;10:406–11.
Manning NW, Cheung A, Phillips TJ, Wenderoth JD. Pipeline shield with single antiplatelet therapy in aneurysmal subarachnoid haemorrhage: Multicentre experience. J Neurointerv Surg. 2019;11:694-8.
Zhu D, Yan Y, Zhao P, Duan G, Zhao R, Liu J, Huang Q. Safety and efficacy of flow diverter treatment for blood blister-like aneurysm: A systematic review and meta-analysis. World Neurosurg. 2018;118:e79–86.
Capocci R, Shotar E, Di Maria F, Rolla-Bigliani C, Al Raaisi A, André A, Mahtout J, Boch AL, Degos V, Sourour N, Clarençon F. Delayed treatment (≥5 days) by flow diversion of ruptured blister-like cerebral aneurysms: Case series of 8 consecutive patients. Clin Neuroradiol. 2019 Jan 25. doi: 10.1007/s00062-019-00758-4. [Epub ahead of print]
Angiolillo DJ, Bhatt DL, Steg PG, Stone GW, White HD, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Mahaffey KW, Harrington RA. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: Insights from the CHAMPION trials. J Thromb Thrombolysis. 2015;40:317–22.
Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial. JAMA. 2012;307:265–74.
Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y12 inhibitors in ACS patients: Who, when, why, and which agent? Eur Heart J. 2016;37:1284–95.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
L. Abdennour, M. Drir, K. Premat, E. Shotar, G. Taylor, A. Godier, J. Mathout, S. Lenck, R. Bernard, A. Carpentier and V. Degos declare that they have no competing interests. F. Clarençon reports conflict of interest with Medtronic, Guerbet, Balt Extrusion (payment for readings), Codman Neurovascular (core lab). N. Sourour is consultant for Medtronic, Balt Extrusion, Microvention, Stock/Stock Options: Medina. The other authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Ethical standards
Patient families were informed before each treatment of the strategy that was chosen and gave verbal consent. The need for patient informed consent for retrospective analyses of records and imaging data was waived by the IRB. This work conforms to the World Medical Association Declaration of Helsinki.
Rights and permissions
About this article
Cite this article
Abdennour, L., Sourour, N., Drir, M. et al. Preliminary Experience with Cangrelor for Endovascular Treatment of Challenging Intracranial Aneurysms. Clin Neuroradiol 30, 453–461 (2020). https://doi.org/10.1007/s00062-019-00811-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00062-019-00811-2